News
PLSE
7.41
+0.54%
0.04
Weekly Report: what happened at PLSE last week (0422-0426)?
Weekly Report · 2d ago
Press Release: Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024. The company will report financial results for the first quarter 2024 after market close on Tuesday, May 7. Company management will host a corresponding conference call for investors to listen to the event. Pulse is a company leveraging its CellFX(R) Nanosecond Pulsed Field Ablation technology.
Dow Jones · 04/24 20:49
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Pulse Biosciences, Inc. Will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024. The company will host a conference call to discuss the results. Pulse is a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation technology.
Barchart · 04/24 15:05
Pulse Biosciences Inc: [Amend]Registration statement under Securities Act of 1933
Press release · 04/23 23:52
Weekly Report: what happened at PLSE last week (0415-0419)?
Weekly Report · 04/22 10:31
Weekly Report: what happened at PLSE last week (0408-0412)?
Weekly Report · 04/15 10:25
Weekly Report: what happened at PLSE last week (0401-0405)?
Weekly Report · 04/08 10:28
Pulse Biosciences to sell subscription rights to purchase up to 6M units
Healthcare Pulse Biosciences to sell subscription rights to purchase up to 6M units for value of up to $60M. ETPulse Bioscience, Inc. (PLSE) files prospectus to sell subscriptions rights to buy up to six million units.
Seeking Alpha · 04/04 14:00
Health Care Sector Update for 04/01/2024: AEON, PLSE, GILD, XLO, EIGR
NASDAQ · 04/01 19:56
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Nuvve Holding Corp. (NASDAQ:NVVE) fell sharply after the company reported worse-than-expected fourth-quarter financial results. The company posted a quarterly loss of $6.98 per share. Vast Renewables Limited shares jumped 179% to $8.62 after jumping 39% on Thursday.
Benzinga · 04/01 18:31
Precision Biosciences, Mesoblast, Pulse Biosciences among healthcare movers
Precision Biosciences, Mesoblast, Pulse Bioscience among healthcare movers. S&P 500 Health Care Sector -0.89% to 1708.7. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index. Health Care Select Sector SPDR® Fund ETF.
Seeking Alpha · 04/01 14:00
Weekly Report: what happened at PLSE last week (0325-0329)?
Weekly Report · 04/01 10:27
Oxford Industries, PVH And 3 Stocks To Watch Heading Into Monday
Wall Street expects PVH Corp. To report quarterly earnings at $3.52 per share on revenue of $2.42 billion. Oxford Industries, Inc. Reported downbeat financial results for its fourth quarter. Torrid Holdings reported better-than-expected fourth-quarter financial results.
Benzinga · 04/01 07:33
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. Sunshine Biopharma stock moved upwards by 39.5% as the company's market cap rose to $8.3 million. Xilio Therapeutics and Medpace Hldgs also rose in the wake of Q4 earnings.
Benzinga · 03/29 20:30
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023
Pulse Biosciences reported earnings per share of -15 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that automates coverage of quarterly earnings reports to help readers understand the figures.
Investorplace · 03/29 02:53
Pulse Biosciences files for $50M mixed securities shelf
Healthcare Pulse Biosciences files for $50M mixed securities shelf Mar. 28, 2024 5:18 PM ETPulse Bioscience, Inc. (PLSE) filed a prospectus related to the offer and sale of $50 million mixed securities.
Seeking Alpha · 03/28 21:18
Pulse Biosciences to initiate rights offering
Healthcare Pulse Biosciences to initiate rights offering of up to $60M worth of units. The rights offering will be available to holders of the company's common stock. The company will receive gross proceeds of $60 million from the rights offering. Pulse Biodesciences, Inc. (PLSE) Stock.
Seeking Alpha · 03/28 20:48
12 Health Care Stocks Moving In Thursday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) shares increased by 73.2% to $1.1 during Thursday's after-market session. Dare Bioscience stock rose 12.19% and Sunshine Biopharma stock increased by 37.85%. Vivos Therapeutics stock fell 12.6% as the company's Q4 earnings came out today.
Benzinga · 03/28 20:31
Pulse Biosciences Q4 EPS $(0.22) Up From $(0.25) YoY
Benzinga · 03/28 20:29
*Pulse Biosciences to Initiate Rights Offering of Up To $60M Worth of Units >PLSE
Dow Jones · 03/28 20:19
More
Webull provides a variety of real-time PLSE stock news. You can receive the latest news about Pulse Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.